ACHVAchieve Life Sciences, Inc.
$7.18+116% 1Y
$7.18
$2.6552 weeks$8.54
ACHV in its own filings
ACHV's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
514
Events found in the filings · across 1,356 filings · the record starts in 1996
- Hard flags
- 2
Hard flags
- Most recent filing
- Oct 1, 2026
Most recent filing · Form 8-K
- Record starts
- May 24, 1996
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountant2 occurrences
- 2017-08-02
- Late periodic reporthistorical
- 2005-03-16
- Delisting notice / listing-rule failure7 occurrences
- 2022-11-25
- SEC comment-letter activity64 occurrences
- 2026-05-19
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 1, 2026On October 1, 2026, Achieve Life Sciences, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Benjamin Halladay as the Company’s Chief Financial Officer and “principal financial officer,” effective as of October 5, 2026 (the “Appointment Date”)Director or officer change · Form 8-K
- Aug 14, 2026On August 14, 2026, Achieve Life Sciences, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (“Common …Other event · Form 8-K
- Aug 11, 2026Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
- Jul 6, 2026On July 6, 2026, following the Annual Meeting of Stockholders (the “Annual Meeting”) of Achieve Life Sciences, Inc. (the “Company”) held on July 2, 2026, the Company filed a certificate of amendment (the “Certificate of Amendment”) to the Company’s third amended certificate of incorporation (the “Certificate of …Charter/bylaw amendment or fiscal-year change · Form 8-K
- Jun 2, 2026Appointment of Board Members On May 29, 2026, the Board of Directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”) appointed Jeff Farrow and Reid Waldman, M.D. (together, the “Incoming Directors”), as directors, effective as of such date.Director or officer change · Form 8-K
- May 12, 2026Appointment of Board Member In connection with the previously reported private placement (the “Private Placement”) of the Company’s securities, and pursuant to the designation right granted to Frazier Life Sciences, on May 11, 2026, the Company’s board of directors (the “Board”) appointed Christopher Martin to serve …Earnings release · Form 8-K
- Apr 16, 2026Securities Purchase Agreement On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors …Material agreement entered · Form 8-K
- Mar 24, 2026Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates.Earnings release · press release
- Nov 6, 2025Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program.Earnings release · press release
- Oct 7, 2025On September 11, 2025, Achieve Life Sciences, Inc. (the “Company”) previously announced that Dr. Cindy Jacobs had informed the Company’s board of directors that she had elected to resign from her role as the Company’s Chief Medical Officer and President, effective as of October 6, 2025 (the “Separation Date”)Director or officer change · Form 8-K
- Sep 11, 2025On September 5, 2025, Dr. Cindy Jacobs informed the board of directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”), that she has elected to resign from her role as the Company’s Chief Medical Officer and President, effective as of October 6, 2025.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…